🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Treatment Acquiring Popularity Online

The experimental drug, which remains in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are encouraged to contact these profiles directly for supplier links, while also obtaining promotional offers.

Thriving Trade on Social Networks

Additionally, a robust market exists on Telegram, where groups with thousands of members share “before and after” images, injection guides and claims of next-day British shipping. Sellers promote the substance there before directing buyers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.

Medical Experts Voice Worries

Nevertheless, doctors and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering substances of unknown origin.

Some professionals stated the popularity for the experimental drug could be connected to the rising price of licensed weight loss products such as Mounjaro.

Legal Status and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach pharmaceutical, advertising, and customer laws, risking fines, prosecution or imprisonment.

Platform Reaction and Content Elimination

According to TikTok, the platform has taken down violative material and banned related hashtags and query recommendations. The organization said it was committed to maintaining the service secure and investing in strengthening compliance measures.

Online Marketplace Activities

Research also discovered groups with up to nine thousand members marketing the experimental drug using the platform's integrated discovery tool, which functions like a online catalog. Typing “retatrutide” immediately brings up channels with thousands of users, filled with images of weight loss, glowing reviews and step-by-step guides for mixing or injecting at home.

Within minutes of entering one community, a vendor shared contact information, where the majority of transactions occur. The vendor provided an guidebook and promised delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one inquired about body mass, health issues or past usage.

Product Details and Costs

Within these communities, messages show black plastic packages with postal service labels, claiming to contain new batches. One message stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with sterile water, or ready-to-use injectors usually priced at £160 for 20 milligrams. When questioned how long a injector should last, vendors give conflicting answers ranging from a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A representative for the messaging service stated it actively moderated harmful content on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they can’t verify. Even if the research behind retatrutide is valid, these digital versions may not include what they claim,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the surge in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With prices rising, patients are using social media. But counterfeit treatments are extremely risky. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she said.

Her team has already encountered patients injured by self-injection from unconfirmed sources. “We understand the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this point no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a company experimental substance not yet approved … may subject patients to potentially significant medical dangers”.